Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Free Cash Flow (2019 - 2025)

Historic Free Cash Flow for Allogene Therapeutics (ALLO) over the last 7 years, with Q3 2025 value amounting to -$29.9 million.

  • Allogene Therapeutics' Free Cash Flow rose 3296.74% to -$29.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$159.0 million, marking a year-over-year increase of 2704.53%. This contributed to the annual value of -$201.0 million for FY2024, which is 1598.96% up from last year.
  • Allogene Therapeutics' Free Cash Flow amounted to -$29.9 million in Q3 2025, which was up 3296.74% from -$39.1 million recorded in Q2 2025.
  • Allogene Therapeutics' 5-year Free Cash Flow high stood at -$29.9 million for Q3 2025, and its period low was -$70.1 million during Q1 2022.
  • For the 5-year period, Allogene Therapeutics' Free Cash Flow averaged around -$52.3 million, with its median value being -$53.0 million (2025).
  • Its Free Cash Flow has fluctuated over the past 5 years, first tumbled by 6864.02% in 2021, then soared by 3843.81% in 2025.
  • Quarter analysis of 5 years shows Allogene Therapeutics' Free Cash Flow stood at -$46.2 million in 2021, then tumbled by 38.15% to -$63.8 million in 2022, then grew by 15.52% to -$53.9 million in 2023, then surged by 31.42% to -$37.0 million in 2024, then grew by 19.2% to -$29.9 million in 2025.
  • Its Free Cash Flow was -$29.9 million in Q3 2025, compared to -$39.1 million in Q2 2025 and -$53.0 million in Q1 2025.